GuruFocus·Aug 11, 2026
TherapeuticsMD Announces Second Quarter 2026 Financial ResultsTherapeuticsMD, Inc. (âTherapeuticsMDâ or the âCompanyâ) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financia
TherapeuticsMD has pivoted to a royalty-dependent business model, resulting in structural gross margins of 100% in most recent quarters, yet the firm remains hampered by fixed administrative expenses that frequently exceed its volatile quarterly revenue. While...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 11, 2026 | $0.01+100.2% vs -$6.13 | $869,000-95.6% vs $20M |
Q2 2026 May 12, 2026 | $0.01+100.2% vs -$6.13 | $724,000-96.3% vs $20M |
Q2 2026 Mar 30, 2026 | -$0.05-233.8% vs $0.04 | $893,000-61.2% vs $2M |
Q4 2025 Nov 12, 2025 | $0.01 vs — | $784,000 vs — |
TherapeuticsMD, Inc. (âTherapeuticsMDâ or the âCompanyâ) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financia
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2026. Second Quarter 2026 Financial Results Net Income from Continuing Operations Net income from continuing operations totaled $164 thousand, compared to net income of $545 thousand for the second quarter of 2025. License Revenues from Continuing Operations The Com.
Benchmark TXMD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for TherapeuticsMD, Inc. (TXMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.16 | $25M | -43.90 | 71.61% | -18.83% | -2.1% | — | |
| $26.24 | $2.06B | 40.37 | 10.4% | 6% | 15.98% | — | |
| $0.85 | $12.66M | -0.71 | 10429.36% | -804.37% | -748.08% | — | |
| $77.91 | $1.77B | 23.47 | 43.78% | 10.82% | 19.19% | — | |
| $3.27 | $20.66M | -2.70 | 125.12% | -115.49% | -61.39% | — | |
| $265.32 | $468.77B | 111.95 | 8.57% | 9.81% | — | — |
TherapeuticsMD, Inc. (TXMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
TherapeuticsMD, Inc. (TXMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 11, 2026·SEC
May 12, 2026·SEC
Mar 30, 2026·SEC
Get notified when TXMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TherapeuticsMD, Inc. (TXMD) stock FAQ — growth, dividends, profitability & financials explained
TherapeuticsMD, Inc. (TXMD) reported $3.3M in revenue for fiscal year 2025. This represents a 1240% increase from $0.2M in 1996.
TherapeuticsMD, Inc. (TXMD) grew revenue by 71.6% over the past year. This is strong growth.
TherapeuticsMD, Inc. (TXMD) reported a net loss of $0.2M for fiscal year 2025.
TherapeuticsMD, Inc. (TXMD) has a return on equity (ROE) of -2.1%. Negative ROE indicates the company is unprofitable.
TherapeuticsMD, Inc. (TXMD) generated $3.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
